Burning Rock Biotech Ltd. (BNR)
Stock Price:
$26.67 USD
-0.32 (-1.19%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.31B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
101.78M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$26.67 |
| Previous Close |
$26.99 |
| Change ($) |
-0.32 |
| Change (%) |
-1.19% |
| Day's Open |
26.81 |
| Day's Range |
25.58 - 26.99 |
| Day's Volume |
282,727 |
| 52-Week Range |
22.50 - 32.40 |
More Stats
| Market Cap |
2.31B |
| Enterprise Value |
2.22B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
101.78M |
| Float |
4.30M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
22.01 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
87.68M |
| Net Cash / Share |
1.01 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
31.1
Current: 26.67
High
31.1
Target: 31.09
*Average 12-month USD price target from 1 stock analysts.
Financial Overview
No financial data available for this stock yet.
Company Details
| Full Name |
Burning Rock Biotech Ltd. |
| Country |
China |
| Employees |
753 |
| CEO |
Yu Sheng Han |
Stock Information
| Ticker Symbol |
BNR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: BNR |
| IPO Date |
June 12, 2020 |
Description
Burning Rock Biotech develops solutions for precision medicine in oncology and early cancer detection in the People's Republic of China. The company provides companion diagnostics for targeted therapy and immunotherapy, benign/malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. It also offers liquid biopsy; OncoScreen Plus, a test for therapy and immunotherapy; LungPlasma, a test for non-small cell lung cancer, including various genes that have a targeted therapy; ColonCore for testing gastrointestinal cancers; and HRDCore for testing genes associated with homologous recombination deficiency. Burning Rock Biotech was founded in 2014 and is headquartered in Guangzhou, China.